BaseClear to Bundle Illumina Data with CLC bio's Software for Next Generation Sequencing Data Analysis

BaseClear to Bundle Illumina Data with CLC bio's Software for Next Generation Sequencing Data Analysis

AARHUS, Denmark & LEIDEN, The Netherlands--(BUSINESS WIRE)--Today, the leading provider of Next Generation Sequencing analysis solutions, CLC bio, announced that the premier Dutch sequencing service center, BaseClear, will provide all customers receiving Next Generation Sequencing data with a license for CLC Genomics Workbench for assembly and downstream sequence analyses.

Commercial Director at BaseClear, Bas Reichert, states, "In order for our customers to get the best possible information out of the Next Generation Sequencing data we produce with our Illumina Genome Analyzer II, we have been looking for a user-friendly solution with a relatively easy learning curve to bundle together with the data. With CLC bio's Genomics Workbench we have found that, and that increased scientific value for our customers is a compelling argument for us to enter an agreement of this type with CLC bio."

Director of Sales, Europe, The Middle East & Africa, at CLC bio, Michel Seidelin, PhD, continues, "Through their excellent service, BaseClear has for many years been the preferred sequencing partner for BeNeLux academic and non-academic laboratories. We're pleased that BaseClear's Next Generation Sequencing customers now will be able to use the world's most user-friendly and comprehensive desktop program, CLC Genomics Workbench, for analysis and visualization of their genomics, transcriptomics, and epigenomics data. This will enable BaseClear's customers to easily assemble, visualize, and perform various downstream analyses of their Next Generation Sequencing data, helping them to rapidly focus on interpreting the biological relevance of their data."

This partnership between CLC bio and BaseClear is the first of many sequencing service centers projected to offer similar services.

About BaseClear

About CLC bio

Suggested Articles

Ipsen's new hire arrives at a company reeling from a torrent six months that have crushed hopes for its $1 billion bet on a rare disease drug.

Leaders from four of the biggest drugmakers in the world spoke about rising to the challenge of defeating the global pandemic.

Bristol Myers Squibb is teaming up with Repare Therapeutics to find new synthetic lethality targets in a deal that could be worth billions.